<DOC>
	<DOC>NCT00346684</DOC>
	<brief_summary>First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab</brief_summary>
	<brief_title>Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>lymphocyte predominant Hodgkin´s lymphoma (histologically proven) clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR &gt; 50mm/h) age 18 75 WHO performance status 03 normal organ function written informed consent classical Hodgkin´s lymphoma composite lymphoma leucocytes &lt; 3000/µl thrombocytes &lt; 100.000/µl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>LPHD</keyword>
	<keyword>Rituximab</keyword>
</DOC>